Company Drug

Bio-Thera Wins NMPA Approval for BAT8008 BAT1006 Trastuzumab Combo Trial – Dual HER2 Trop2 Targeting in Advanced Solid Tumors

By Fineline Cube #ADC / XDC #Bio-Thera Solutions #Cancer #Clinical trial approval / initiation #Combination therapy #SHA: 688177

Bio-Thera Solutions Ltd (SHA: 688177) announced NMPA clearance to initiate a clinical study evaluating BAT8008 (anti-Trop2 ADC) combined with BAT1006 (anti-HER2 antibody) plus trastuzumab in HER2-positive advanced solid tumors. The triplet regimen represents a novel dual-HER2/Trop2 targeting strategy leveraging Bio-Thera’s proprietary ADC platform and bispecific-like antibody engineering to address tumor heterogeneity in refractory cancers.

Regulatory Milestone

ItemDetail
AgencyNMPA (China)
Approval TypeClinical trial authorization (IND)
Study DesignBAT8008 + BAT1006 + trastuzumab combination
IndicationHER2-positive advanced solid tumors
DeveloperBio-Thera Solutions Ltd (SHA: 688177)
Approval DateMarch 2026

Product Profiles & Mechanism

BAT8008 (Anti-Trop2 ADC)

AttributeSpecification
StructureRecombinant humanized anti-Trop2 antibody + topoisomerase I inhibitor payload
LinkerSelf-developed cleavable linker
MechanismTargeted delivery of cytotoxic payload to Trop2-expressing tumor cells
Key FeatureStrong bystander effect – toxin diffusion kills neighboring antigen-negative cells, overcoming tumor heterogeneity
ActivityEfficient anti-tumor activity in preclinical models

BAT1006 (Anti-HER2 Antibody)

AttributeSpecification
TargetHER2 extracellular dimerization domain (Subdomain II)
MechanismBlocks ligand-dependent HER2 heterodimerization with EGFR, HER3, HER4
Downstream EffectInhibition of MAP kinase and PI3K signaling pathways
OutcomeCell growth arrest and apoptosis
DifferentiationNovel epitope targeting vs. trastuzumab (Subdomain IV)

Trastuzumab (Herceptin)

| Role | Established anti-HER2 backbone; Fc-mediated immune effector functions |

Combination Rationale & Strategic Value

ComponentContribution to Triplet
TrastuzumabHER2 signaling blockade (Subdomain IV) + ADCC-mediated tumor killing
BAT1006Complementary HER2 dimerization blockade (Subdomain II); broader HER family inhibition
BAT8008Trop2-directed cytotoxic payload; bystander effect addresses HER2-negative tumor clones

Scientific Synergy:

  • Dual HER2 blockade: Trastuzumab + BAT1006 target distinct epitopes → comprehensive HER2 pathway shutdown
  • Dual antigen targeting: HER2 + Trop2 co-expression in many solid tumors (breast, gastric, urothelial)
  • Heterogeneity solution: Bystander effect from BAT8008 payload addresses antigen-loss variants

Competitive Context

FactorMarket Implication
ADC LandscapeTrop2 ADCs (sacituzumab govitecan, datopotamab deruxtecan) approved; BAT8008 differentiated by proprietary linker/payload
HER2 InnovationBAT1006’s Subdomain II binding offers mechanism complementary to established antibodies
Combination TrendADC + immune checkpoint or targeted therapy combinations gaining traction; triplet with dual HER2 blockade novel
China PositioningBio-Thera advances domestic ADC innovation; potential for global partnership on differentiated platform

Development Outlook

  • Phase I Design: Dose-escalation of triplet combination; biomarker-enriched HER2-positive solid tumor cohorts
  • Expansion Cohorts: Breast cancer, gastric cancer, urothelial carcinoma prioritized based on HER2/Trop2 co-expression
  • Manufacturing: Bio-Thera’s integrated ADC facility supports clinical and commercial supply
  • Global Strategy: China-first development; U.S./EU IND filing contingent on Phase I safety/efficacy data

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, combination efficacy, and partnership potential for Bio-Thera’s BAT8008 and BAT1006 programs. Actual results may differ due to trial outcomes, competitive dynamics, and manufacturing complexities.-Fineline Info & Tech

688177_20260307_4A07Download

Related Post

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Fineline Cube
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube
Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Fineline Cube

You Missed

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Company Drug

Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations